Inhalers for chronic obstructive pulmonary disease (COPD) are a mainstay of treatment. These medications are inhaled through ...

The Biden administration has reformed Medicare, gone after bogus drug patents and pushed pharmaceutical companies to reduce ...

Poor treatment of asthma and COPD puts a huge burden on the NHS. For example, £1 billion is spent on asthma treatment in the UK each year and represents 60,000 to 65,000 hospital admissions. In ...

While people with asthma or chronic obstructive pulmonary disease (COPD) can experience worse symptoms due to climate change, many of the medications they’re prescribed also contribute to ...

We are building upon our strong heritage in bronchodilator and inhaler development with ongoing clinical development programmes aimed at improving the outlook for people with COPD. COPD is a ...

awareness of the consequences of generic prescribing of inhalers and specific examples of problems which have arisen. Interviews with community pharmacists will provide data about dispensing ...

A new analysis that compares two common inhalers for patients suffering from chronic obstructive pulmonary disease (COPD) finds that one reduces respiratory-related hospitalizations and ...

Qualcomm and its rival Propeller are emerging as the tech companies to partner with in the development of smart inhalers. Virtually all the companies active in the asthma and COPD markets have ...

Generic prescription drugs are lower priced than brand-name medications that no longer have a patent. Generic medications are considered as effective as their brand-name counterparts. Part D is ...

AstraZeneca recently announced the completion of clinical studies for a next-generation propellant (NGP) version of its chronic obstructive pulmonary disease (COPD) inhaler, Breztri. This new ...